<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>Access Pharmaceuticals, Inc. Newsroom</title>
	<link>http://www.accesspharma.com/newsroom</link>
	<description>Breaking News, stock info, SEC filings, multimedia and other information on Access Pharmaceuticals, Inc.</description>
	<lastBuildDate>Wed, 07 Dec 2011 15:26:40 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.2.1" -->

	<item>
		<title>MUGARD ADVOCATE INTERVIEWED ON  ABC TAMPA NEWS AT NOON</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Investor Call to Be Held Today at 11:00am EST Dallas, TX and New York, NY, December 7, 2011 &#8211; ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that an oncology supportive care [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/mugard-advocate-interviewed-on-abc-tampa-news-at-noon/</link>
			</item>
	<item>
		<title>Access Pharmaceuticals Provides Third Quarter Update on MuGard Commercial Activities</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Company Schedules Investor Conference Call For Wednesday, December 7th at 11:00AM EST DALLAS and NEW YORK, November 15, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, has announced its third quarter 2011 investor conference [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-provides-third-quarter-update-on-mugard-commercial-activities/</link>
			</item>
	<item>
		<title>Access Pharmaceuticals Announces Private Placement of $5.2 Million</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Dallas and New York, November 2, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it has entered into definitive agreements for the purchase of $5.2 million of units, consisting of Access [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-announces-private-placement-of-5-2-million/</link>
			</item>
	<item>
		<title>Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Dallas and New York, October 14, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has updated its MuGard website to include a clinical feedback video.  The video features a late-stage colorectal patient and [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-updates-mugard-website-with-new-video-featuring-clinical-feedback-and-manufacturing-footage/</link>
			</item>
	<item>
		<title>Access Pharmaceuticals Provides Update on Increasing Payer Uptake for MuGard</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Recent MuGard Reimbursement More Than Doubles Over the Past Few Months Dallas and New York, October 13, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the reimbursement for its lead product [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-provides-update-on-increasing-payer-uptake-for-mugard/</link>
			</item>
	<item>
		<title>Access Pharmaceuticals Reports Additional MuGard Study Findings Presented at EMCC 2011 in Stockholm</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Dallas and New York, September 28, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced the findings of an independent presentation on MuGard clinical experience at the 2011 European Multidisciplinary Cancer Congress held [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/1047/</link>
			</item>
	<item>
		<title>Access Pharmaceuticals and CuraScript Team Up to Further Expand MuGard Market Access and Distribution</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Dallas and New York, NY, September 07, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it has contracted with CuraScript, a healthcare subsidiary of  Express Scripts (NasdaqGS:ESRX), to expand its specialty [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-and-curascript-team-up-to-further-expand-mugard-market-access-and-distribution/</link>
			</item>
	<item>
		<title>ACCESS PHARMACEUTICALS TO PRESENT AT RODMAN &amp; RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE ON MONDAY, SEPTEMBER 12TH IN NEW YORK CITY</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Investor Call Scheduled for Tomorrow, Wednesday, September 7th at 11:00 a.m. EDT Dallas, TX and New York, NY, September 06, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the Company’s [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-to-present-at-rodman-renshaw-annual-global-investment-conference-on-monday-september-12th-in-new-york-city/</link>
			</item>
	<item>
		<title>ACCESS PHARMACEUTICALS PROVIDES SECOND QUARTER UPDATE ON MUGARD COMMERCIAL ACTIVITIES</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Company Schedules Investor Conference Call For Wednesday, September 7th at 11:00AM EDT Dallas, TX and New York, NY, August 16, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, has announced its second quarter 2011 [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-provides-second-quarter-update-on-mugard-commercial-activities/</link>
			</item>
	<item>
		<title>ACCESS PHARMACEUTICALS RETAINS EDELMAN AS PUBLIC RELATIONS FIRM</title>
		<description><![CDATA[Email Print Tweet Digg! Del.icio.us Public Relations Firm Focused on Increasing Media Awareness of Company’s Oral Mucositis Treatment Dallas, TX and New York, NY, August 05, 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has hired Edelman, [...]]]></description>
		<link>http://www.accesspharma.com/newsroom/access-pharmaceuticals-retains-edelman-as-public-relations-firm/</link>
			</item>
</channel>
</rss>

